Literature DB >> 32234611

3-Dimensional target coverage assessment for MRI guided esophageal cancer radiotherapy.

M R Boekhoff1, I L Defize2, A S Borggreve2, N Takahashi3, A L H M W van Lier4, J P Ruurda5, R van Hillegersberg5, J J W Lagendijk4, S Mook4, G J Meijer6.   

Abstract

PURPOSE: This study aimed to quantify the coverage probability for esophageal cancer radiotherapy as a function of a preset margin for online MR-guided and (CB)CT-guided radiotherapy.
METHODS: Thirty esophageal cancer patients underwent six T2-weighted MRI scans, 1 prior to treatment and 5 during neoadjuvant chemoradiotherapy at weekly intervals. Gross tumor volume (GTV) and clinical target volume (CTV) were delineated on each individual scan. Follow-up scans were rigidly aligned to the bony anatomy and to the clinical target volume itself, mimicking two online set-up correction strategies: a conventional CBCT-guided set-up and a MR-guided set-up, respectively. Geometric coverage probability of the propagated CTVs was assessed for both set-up strategies by expanding the reference CTV with an isotropic margin varying from 0 mm to 15 mm with an increment of 1 mm.
RESULTS: A margin of 10 mm could resolve the interfractional changes for 118 out of the 132 (89%) analyzed fractions when applying a bone-match registration, whereas the CTV was adequately covered in 123 (93%) fractions when the registration was directly performed at the CTV itself (soft-tissue registration). Closer analyses revealed that target coverage violation predominantly occurred for distal tumors near the junction and into the cardia.
CONCLUSION: Online MR-guided soft-tissue registration protocols exhibited modest improvements of the geometric target coverage probability as compared to online CBCT-guided bone match protocols. Therefore, highly conformal target irradiation using online MR-guidance can only be achieved by implementing on-table adaptive workflows where new treatment plans are daily generated based on the anatomy of the day.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adaptive radiotherapy; Esophageal cancer; Interfractional motion; MR guided radiation therapy; Treatment margin

Mesh:

Year:  2020        PMID: 32234611     DOI: 10.1016/j.radonc.2020.03.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

Review 1.  Adaptive proton therapy.

Authors:  Harald Paganetti; Pablo Botas; Gregory C Sharp; Brian Winey
Journal:  Phys Med Biol       Date:  2021-11-15       Impact factor: 3.609

2.  In-Air Electron Streaming Effect for Esophageal Cancer Radiotherapy With a 1.5 T Perpendicular Magnetic Field: A Treatment Planning Study.

Authors:  Hongdong Liu; Shouliang Ding; Bin Wang; Yongbao Li; Ying Sun; Xiaoyan Huang
Journal:  Front Oncol       Date:  2020-12-01       Impact factor: 6.244

3.  Review of MR-Guided Radiotherapy for Esophageal Cancer.

Authors:  Sangjune Laurence Lee; Michael Bassetti; Gert J Meijer; Stella Mook
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

4.  Geometrical Comparison and Quantitative Evaluation of 18F-FDG PET/CT- and DW-MRI-Based Target Delineation Before and During Radiotherapy for Esophageal Squamous Carcinoma.

Authors:  Huimin Li; Jianbin Li; Fengxiang Li; Yingjie Zhang; Yankang Li; Yanluan Guo; Liang Xu
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

5.  Clinical implementation and feasibility of long-course fractionated MR-guided chemoradiotherapy for patients with esophageal cancer: An R-IDEAL stage 1b/2a evaluation of technical innovation.

Authors:  M R Boekhoff; R Bouwmans; P A H Doornaert; M P W Intven; J J W Lagendijk; A L H M W van Lier; M J A Rasing; S van de Ven; G J Meijer; S Mook
Journal:  Clin Transl Radiat Oncol       Date:  2022-03-17

Review 6.  Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation.

Authors:  Francesco Cellini; Stefania Manfrida; Calogero Casà; Angela Romano; Alessandra Arcelli; Alice Zamagni; Viola De Luca; Giuseppe Ferdinando Colloca; Andrea D'Aviero; Lorenzo Fuccio; Valentina Lancellotta; Luca Tagliaferri; Luca Boldrini; Gian Carlo Mattiucci; Maria Antonietta Gambacorta; Alessio Giuseppe Morganti; Vincenzo Valentini
Journal:  Cancers (Basel)       Date:  2022-01-15       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.